ESC Diabetes and Cardiovascular Disease

In which patient category is it recommended to screen for diabetes using fasting glucose and/or HbA1c?

All individuals with a family history of diabetes
All individuals over the age of 50
All individuals with cardiovascular disease (i.e. any atherosclerotic disease, heart failure and atrial fibrillation)
All individuals with a BMI over 30
South Asians with a BMI over 27

Which of the following is recommended for screening diabetes in individuals with cardiovascular disease (CVD)?

For which condition is it recommended to screen patients with diabetes?

Which of the following criteria is not included in the definition of severe target-organ damage (TOD) in patients with type 2 diabetes?

Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² irrespective of albuminuria
eGFR 45–59 mL/min/1.73 m² and microalbuminuria (urinary albumin-to-creatinine ratio [UACR] 30–300 mg/g; stage A2)
Proteinuria (UACR >300 mg/g; stage A3)
Presence of microvascular disease in at least three different sites (e.g., microalbuminuria (stage A2) plus retinopathy plus neuropathy)
Coronary artery calcium (CAC) score >300

Which patient category is defined as having a very high cardiovascular (CV) risk in type 2 diabetes?

Patients with T2DM and 10-year CVD risk 5 to <10% using SCORE2-Diabetes
Patients with T2DM and no established ASCVD or severe TOD
Patients with T2DM and clinically established ASCVD, severe TOD, or 10-year CVD risk ≥20% using SCORE2-Diabetes
Patients with T2DM and 10-year CVD risk 10 to <20% using SCORE2-Diabetes
Patients with T2DM and 10-year CVD risk <5% using SCORE2-Diabetes

For which patient group is the use of the SCORE2-Diabetes algorithm recommended to estimate 10-year cardiovascular disease (CVD) risk?

Why should SCORE2-Diabetes not be used in patients with diabetes and ASCVD or severe TOD?

SCORE2-Diabetes underestimates risk in that group.
SCORE2-Diabetes overestimates risk in that group.
SCORE2-Diabetes has low area under the receiver operating characteristics curve (AU-ROC) in that group.
SCORE2-Diabetes has low sensitivity and specificity in that group.
Individuals with diabetes and ASCVD or severe TOD are already at very high risk, and SCORE2-Diabetes is of no further utility to them.